EGFR anticorps (Extracellular Domain) (FITC)

N° du produit ABIN181808

L’anticorps Rat Monoclonal anti-EGFR a été validé pour FACS. Il convient pour détecter EGFR dans des échantillons de Humain.

Aperçu rapide pour EGFR anticorps (Extracellular Domain) (FITC) (ABIN181808)

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reactivité: Humain

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Clone: ICR10

Détail du produit anti-EGFR anticorps (FITC)

Épitope: Extracellular Domain

Specificité: This antibody recognises the Epidermal Growth Factor Receptor (EGF-R), which is over expressed in a high proportion of breast cancer cells and in a range of other carcinomas. High level expression of EGFR is often associated with advanced disease and poor prognosis. The antibody binds to epitope B from EGFR (1,2).Aff. Const.:6.7 x 10e-9 M

Purification: Ion Exchange Chromatography.

Immunogène: Extracellular domain of human EGF-receptor from head and neck carcinoma

Isotype: IgG2a

Information d'application

Indications d'application: Flow Cytometry: Use 10 μL of 1/10 diluted antibody to label 10^6 cells in 100 μL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 0.1 mg/mL

Buffer: PBS, pH 7.4 containing 0.09 % Sodium Azide as preservative and 1 % BSA as stabilizer.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing. Dilute only prior to immediate use

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur EGFR

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Autre désignation: EGFR / ERBB1

Sujet: EGF Receptor (EGFR) and erbB2, erbB3, and ErbB4 are members of subclass I of receptor tyrosine kinases. EGFR/erbB receptors are activated upon binding of EGF and EGF-related growth factors such as TGF alpha, beta-cellulin, Hb-EGF, HRG, or NRG. Binding of these ligands leads to receptor homo- and heterodimerization followed by autophosphorylation and activation of downstream signal transduction pathways (MAPK, PI3K/PKB, and STAT). In addition, EGFR becomes fully activated after phosphorylation of Y845 by src family kinases. Phosphorylation of Y1045 leads to association with cbl and subsequent receptor degradation. Phosphorylation of S1047 by CamKinase II leads to attenuation of kinase activity, phosphorylation of T654 (by PKC) and T669 (by MAPK, p38) interferes with receptor endocytosis/recycling.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1

ID gène: 1956

NCBI Accession: NP_005219

UniProt: P00533

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins